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The year 2000 marks not only 125 years since Kahlbaum's monograph 1 on catatonia, and 40 years since Delay et al 2 first described the neuroleptic malignant syndrome (NMS), but also an important year for the study of catatonia and NMS.
Catatonia is no longer an archaic form of schizophrenia. It is found in patients on medical wards, emergency rooms, clinics, and psychiatric facilities. Furthermore, NMS has been conceptualized as a severe, drug-induced form of catatonia by a recent comprehensive review. 3 Catatonia has been considered to be a significant risk factor for NMS. We are grateful to CNS Spectrums for the opportunity to present our finding and advance the study of catatonia and NMS.
While catatonia and NMS are uncommon neuropsychiatric disorders, clinicians should be aware of these diagnoses and their complications. Catatonia and NMS are related conditions that share differential diagnosis, treatment, and proposed pathophysiology. The neurochemical and neuroanatomic findings in catatonia have been limited and, at times, conflicting. This issue of CNS Spectrums attempts to unify new findings into a concept of catatonia and NMS as manifestations of a single clinical entity.
Catatonia responds favorably to treatment with benzodiazepines, such as lorazepam, and to electroconvulsive therapy. It may also respond to treatment directed at the underlying psychiatric and medical disorders. Why does catatonia respond to an anxiolytic medication like lorazepam? And, if catatonia does not improve after treatment with benzodiazepines, what does this tell us about the neurochemical systems that mediate catatonia?
These are baffling questions. The mechanisms of lorazepam, a y-aminobutyric acid (GABA) agonist, has been described in catatonia and the role of dopamine hypoactivity has been discussed in the development of NMS. M However, there has been little effort to incorporate these prominent neurochemical systems as they relate to catatonia and NMS. The universal field hypothesis attempts to integrate disparate findings of these related disorders. If catatonia and NMS result from imbalances in the GABA, dopamine, serotonin, and glutamate systems, this would explain their clinical and treatment similarities.
The second paper, investigates the functional neuroanatomical basis for catatonia. Georg Northoff, MD, PhD, and his research team have performed a large number of brain imaging studies involving patients with catatonia. He synthesizes these findings in order to apply them to the motor, affective, and behavioral signs in patients with catatonia.
Stephanie Krilger, MD, and Peter Bra"unig, MD, present their findings on catatonia in affective disorders. Affective disorders represent the most frequent psychiatric diagnosis in patients presenting with catatonia, especially acute catatonia. This relationship between affective disorder and catatonia is important for clinicians who treat these patients.
The relationship between catatonia and NMS is frequently discussed but rarely studied. These two research teams, operating in two different settings, address questions regarding these disorders. Andrew Francis, MD, PhD, and colleagues ask: 1) Does catatonia occur in NMS? and 2) Does lorazepam, a treatment for catatonia, show efficacy in treating NMS? Denise A. C. White, MBChB, MMed, FCPsych(SA), and Ashley H. Robins, MBChB, MRCPsych, ask: E patients who present with acute catatonia are treated with an antipsychotic, do they develop NMS?
Catatonia due to a general medical condition was added to the Diagnostic and Statistical Manual, Fourth Edition, and is found in the International Classification of Diseases, 10th Edition, as organic catatonia (ie, medical catatonia). While this "nonpsychiatric catatonia" is an uncommon form of catatonia that is not frequently included in most studies of patients with catatonia, it remains a concern for clinicians treating patients with catatonia. We pose the question: Does medical catatonia look any different than psychiatric catatonia?
We have also included a case study with neuropathologic findings. In the early 1990s, we had difficulty explaining these results because they did not fit into the existent neuropathological hypotheses for catatonia. However, using the model of Lauterbach, we can now identify the role of the thalamus in the development of catatonia.
